Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (340)	7/2/1998 1:27:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 586

Here is the post from Yahoo: "Here are the highlights. My impressions of management - Highly capable, responsive to shareholder concerns, totally focused on the successful launch of Prosorba for RA. Marketing plan - They intend to form a partnership with a manufacturer of apheresis machines and market a package of the machine and the column to high volume rheumatology practices and dialysis centers. The partner will handle actual sales, CYPB's sales force will detail the package to potential customers. They believe that doing the procedure in a hospital setting is too expensive, and that rheumatologists will look on the package as a profit opportunity, much as GI docs do with their endoscopy machines. Pricing - The production cost of the column will come down significantly with larger volume production, allowing for price reductions without reducing the current gross margin on the column (about 40%). Third party payers - They are working on this, but can't get commitments prior to approval. Use of the column is reimbursed for ITP. Approval - They expect a review panel in Feb. '99 with approval to follow in mid '99. Finances - They expect to be able to finance continuing operations and the RA launch and sales without dilution. Prosorba market size - 120,000 - 300,000 columns per year in the US market. International - Will be addressed after successful launch in the US. Cyplex - The Cyplex program has been slowed down in order to devote all of their resources to the RA launch. Approval and launch is now expected in 2002. Cyplex markets - Oncology, hemophilia, ITP, aplastic anemia and myelodysplasia. Target $200-500mm per year. Reverse split - Authorized, but they won't do it except as a part of a major financing package or until after they have commercial sales for RA. There were some other announcements which are in their press releases of yesterday, so I won't repeat them here. If you have questions, please post them. "